Search results
Moderna, Merck Reveal Three Year Data For Individualized Cancer Therapy In High-Risk Melanoma...
Benzinga via Yahoo Finance· 1 day agoMonday, Moderna Inc (NASDAQ:MRNA) and Merck & Co Inc (NYSE:MRK) announced the first presentation of...
Moderna and MSD share encouraging three-year data from trial of melanoma therapy
Clinical Trials Arena via Yahoo Finance· 18 hours agoPharmaceutical companies Moderna and Merck & Co (MSD) have announced positive results from the Phase...
An mRNA Melanoma Vaccine Shows Promise
Time Magazine· 2 days agoModerna says the same mRNA technology that fueled its COVID-19 vaccine is proving effective in fighting melanoma. The company presented the latest...
Is Moderna Stock A Buy As The U.S. Government Mulls Its Bird Flu Vaccine?
Investor's Business Daily· 5 days agoModerna confirmed it's in discussions with the U.S. government to move forward with its bird flu...
Moderna Wins Second-Ever Approval. But It Could Dominate Pfizer, GSK.
Investor's Business Daily· 4 days agoLike rivals Pfizer (PFE) and GSK (GSK) — which gained their approvals and launched last year — ...
US FDA approves Moderna's RSV vaccine with lower-than-expected efficacy in its label
Reuters· 4 days ago, opens new tab respiratory syncytial virus (RSV) vaccine, the company announced on Friday, giving...
Moderna, Merck say vaccine improved survival in patients with deadly skin cancer
CNBC· 2 days agoModerna and Merck released more positive three-year data Monday on their experimental vaccine, given...
Why Moderna Stock Is Sinking This Week
Motley Fool via Yahoo Finance· 5 days agoShares of Moderna (NASDAQ: MRNA) were sinking 9% lower this week as of Thursday's market close, according to data provided by S&P Global Market...
US nears deal to fund Moderna's bird flu vaccine trial, FT reports
Reuters via Yahoo News· 6 days agoModerna told Reuters it was in discussions with the government on advancing its vaccine candidate,...
The Moderna Selloff Gains Steam. An Analyst Has a Few Theories Why.
Barrons.com· 6 days agoWhat began Tuesday as a puzzling dip in shares of the biotech Moderna accelerated into a larger...
